此乃要件 請即處理 閣下如對本通函任何方面或應採取的行動有任何疑問，應諮詢 閣下的持牌證券交易商、銀行經理、律師、專業 會計師或其他專業顧問。 閣下如已將名下的百本醫護控股有限公司股份全部售出或轉讓，應立即將本通函及隨附的代表委任表格送交或轉 交買方或承讓人，或經手買賣或轉讓的銀行、持牌證券交易商或其他代理商，以便轉交買方或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不就因本通函全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 BAMBOOS HEALTH CARE HOLDINGS LIMITED 百本醫護控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2293） 建議 (1)發行及購回股份的一般授權； (2)重選退任董事； (3)續聘核數師； (4)宣派末期股息； 及 (5)股東週年大會通告 本公司謹訂於二零二四年十一月二十八日（星期四）上午十一時正在香港九龍旺角彌敦道612–618號好望角大廈8樓 801室舉行股東週年大會（定義見下文），大會通告載於本通函第AGM-1頁至第AGM ...

Financial Performance - The company's revenue for the year was approximately HKD 94.8 million, a decrease of about 25.1% compared to HKD 126.6 million for the year ended June 30, 2023[8]. - Profit attributable to equity holders for the year was approximately HKD 30.9 million, down about 34.1% from approximately HKD 46.9 million for the year ended June 30, 2023[8]. - Revenue from healthcare staffing solutions was approximately HKD 77.3 million, a decrease of about 25.0% from approximately HKD 103.0 million for the year ended June 30, 2023[8]. - Revenue from outreach case assessment and vaccination services decreased by approximately 33.1% to about HKD 8.2 million, primarily due to the government's withdrawal of COVID-19 control measures[8]. - Total revenue for the year was approximately HKD 94,800,000, a decrease of about 25.1% from approximately HKD 126,600,000 for the year ending June 30, 2023[10]. - The profit for the year was approximately HKD 30,900,000, a decrease of about HKD 16,000,000 or 34.1% from approximately HKD 46,900,000 for the year ending June 30, 2023[15]. - The net profit margin decreased from approximately 37.1% to about 32.6%[15]. - Other income for the year was approximately HKD 1,500,000, a significant decrease from HKD 9,000,000 the previous year, primarily due to the absence of event-related income[12]. - Employee benefits expenses were approximately HKD 26,000,000, down from HKD 38,700,000 the previous year[13]. - Cash and cash equivalents were approximately HKD 81,100,000 as of June 30, 2024, down from HKD 93,300,000 the previous year[18]. Business Strategy and Operations - The company has established a service platform called "HealthHub" in Mong Kok, integrating healthcare and smart home AI technology[5]. - The company is focused on diversifying its business and enhancing personalized market services while expanding its operational footprint[5]. - The company aims to improve community healthcare standards and fulfill its social responsibility through comprehensive services centered on family health[5]. - The company is committed to maintaining robust financial management principles to support ongoing business expansion and future development[4]. - The company aims to enhance its core business and become a more recognized market leader through strategic partnerships and business diversification[9]. Corporate Governance - The company maintains high standards of corporate governance and compliance with applicable codes[31]. - The board held four meetings during the year, with all directors attending 100% of the meetings[41]. - The Audit Committee conducted three meetings, with all members present at each meeting[44]. - The Remuneration Committee held one meeting, with full attendance from all members[46]. - The Nomination Committee met twice during the year, with all members present at each meeting[48]. - The company confirmed the independence of all non-executive directors in accordance with listing rules[39]. - The board is committed to diversity in its composition, considering factors such as age, gender, and professional experience[47]. - The board is responsible for overseeing the company's overall strategy and financial performance[42]. - The board has adopted a diversity policy, ensuring that 37% of employees are male and 63% are female, reflecting a reasonable gender balance[49]. Environmental, Social, and Governance (ESG) Initiatives - The board is committed to monitoring and improving the company's environmental, social, and governance (ESG) performance, ensuring transparency and accountability[86]. - The company emphasizes the importance of stakeholder engagement and has set directional environmental goals to track progress[85]. - The ESG report adheres to the principles of materiality, quantification, balance, and consistency, ensuring meaningful comparisons of data[77]. - The company is actively pursuing a low-carbon economy transition, aiming to reduce greenhouse gas emissions in both the short and long term[84]. - The company has received multiple awards recognizing its commitment to providing excellent products and services[83]. - The report includes a commitment to fostering a culture of diversity and inclusion, valuing diverse perspectives and contributions[84]. - The company aims to enhance its internal data collection processes to ensure a comprehensive performance overview[76]. - The ESG working group is composed of the CEO, CFO, and COO, responsible for overseeing and evaluating the group's ESG procedures and risk management[87]. - The group conducts an annual materiality assessment to understand stakeholders' opinions and expectations regarding ESG issues, which helps in sustainable development planning[88]. - The ESG working group reviews the progress of goals regularly, and if there are significant discrepancies, strategies will be revised accordingly[89]. Employee and Labor Practices - The number of registered healthcare personnel increased to approximately 29,800 as of June 30, 2024, up by about 2,800 or 10.4% from 27,000 the previous year[9]. - The employee turnover rate as of June 30, 2024, is 16% for males and 19% for females, showing a decrease from the previous year[128]. - The company has a total of 55 employees as of June 30, 2024, down from 60 in the previous year[128]. - The company has not reported any violations of labor laws related to compensation, hiring, or discrimination during the year[128]. - The company is committed to respecting international human rights and has not encountered any cases of child labor or forced labor violations during the year[129]. - 100% of employees received training in the current year, with a total of 2,416 training hours provided[135]. - The percentage of trained employees by gender: 35% male and 65% female in 2024[135]. - Average training hours per employee: 43.2 hours for males and 44.3 hours for females in 2024[135]. Community Engagement - The group has contributed HKD 25,000 in cash and HKD 89,000 in kind to community support initiatives in 2023[147]. - The group actively participated in various community activities, including supporting vaccination programs and sponsoring healthcare events[147]. - The group has received the 10-year Plus "Caring Company" logo, reflecting its commitment to social responsibility and community engagement[146]. - The group emphasizes the importance of community involvement for sustainable development and social inclusivity[146]. Shareholder Information - The company declared a final dividend of HKD 15,000,000 (HKD 0.0375 per share) for the year, compared to HKD 0.0500 per share in 2022[165]. - The total bank borrowings as of June 30, 2024, amounted to HKD 63,100,000, a decrease from HKD 65,500,000 in 2023[166]. - The company's distributable reserves were approximately HKD 20,318,000 as of June 30, 2024, down from HKD 29,691,000 in 2023[166]. - The company has not purchased, redeemed, or sold any of its listed securities during the year and up to the date of this report[167]. Stock Options and Incentive Plans - The company has granted stock options to directors, with a total of 1,850,000 shares at an exercise price of HKD 1.440 and 2,000,000 shares at HKD 0.994[179]. - The stock options granted to directors represent 0.460% and 0.500% of the total shares respectively[179]. - The stock option plan was approved by shareholders on June 24, 2014, and aims to reward eligible participants contributing to the group[183]. - The maximum number of shares that can be issued under the stock option plan is capped at 40,000,000, which is 10% of the total shares issued at the time of the plan's adoption[184]. - The stock incentive plan allows for a maximum of 40,000,000 shares to be granted, which is 10% of the total issued shares at the time of the plan's adoption[192]. - The total number of stock options exercised during the year is zero, indicating no stock options were utilized[189]. - The company aims to attract suitable talent and retain existing employees through the stock incentive plan[190]. Compliance and Risk Management - The company has a zero-tolerance policy towards corruption, including bribery and fraud, with a reporting system for employees to raise concerns[64]. - The company has established procedures for handling and disclosing inside information to ensure accuracy and timeliness[65]. - The company secretary has completed no less than 15 hours of professional training to update skills and knowledge[66]. - The company has implemented a comprehensive policy and procedures to manage product and service responsibilities, ensuring quality and safety[138]. - The group has implemented strict measures to protect personal data, ensuring confidentiality and preventing unauthorized access[141]. - The group has established robust procedures to protect intellectual property, ensuring all software is sourced from authorized suppliers[142].

BAMBOOS HEALTH CARE HOLDINGS LIMITED , 25 October 2024 The following document(s) of Bamboos Health Care Holdings Limited (the "Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.bamboos.com.hk and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites"):- • Annual Report 2024 • Circular dated 25 October 2024 in relation to Proposals for (1) General Mandates to Issue and Buy-back Shares; (2) Re-election of Retiring Di ...

BAMBOOS HEALTH CARE HOLDINGS LIMITED 百本醫護控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 2293) NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), 25 October 2024 The following document(s) of Bamboos Health Care Holdings Limited (the "Company") has/have been prepared in English and Chinese and is/are available on the websites of the Company at www.bamboos.com.hk and The Stock Exchange of Hong Kong Limited at www.hkexnews.hk (collectively "Websites") ...

Financial Performance - For the fiscal year ending June 30, 2024, the revenue was approximately HKD 94.8 million, a decrease of about 25.1% compared to HKD 126.6 million for the fiscal year ending June 30, 2023[1]. - The profit before tax for the fiscal year ending June 30, 2024, was approximately HKD 39.2 million, down approximately 33.2% from HKD 58.7 million for the previous year[1]. - The profit attributable to equity holders for the fiscal year ending June 30, 2024, was approximately HKD 30.9 million, a decrease of about 34.1% compared to HKD 46.9 million for the fiscal year ending June 30, 2023[1]. - The basic earnings per share for the fiscal year ending June 30, 2024, was HKD 0.0773, compared to HKD 0.1173 for the previous year[2]. - The group reported a net profit of HKD 30.9 million for the fiscal year ending June 30, 2024, compared to HKD 46.9 million for the previous year[3]. - Total revenue for the group in 2024 was HKD 94,787 thousand, a decline of 25% compared to HKD 126,558 thousand in 2023[11]. - Revenue from healthcare staffing solutions decreased to HKD 77,346 thousand in 2024, down 25% from HKD 102,998 thousand in 2023[11]. - Other income in 2024 was HKD 1,508 thousand, significantly lower than HKD 8,997 thousand in 2023, reflecting a decline of approximately 83.2%[13]. - The net loss from other losses was approximately HKD 1.3 million, compared to a loss of HKD 1.0 million in the previous year[42]. Dividends - The proposed final dividend for the fiscal year ending June 30, 2024, is HKD 0.025 per share, down from HKD 0.0375 per share for the previous year[1]. - The company declared a final dividend of HKD 15,000,000 for the year, impacting retained earnings[6]. - The company plans to pay an interim dividend of HKD 20,123,000 (HKD 5.00 per share) for the year 2024[21]. - The company proposed a final dividend of HKD 2.50 per share for the current year, compared to HKD 3.75 in the previous year[71]. - Total dividends for the year amount to HKD 7.50 per share, unchanged from the previous year[72]. Assets and Liabilities - Total assets as of June 30, 2024, were HKD 318.1 million, a decrease from HKD 346.8 million as of June 30, 2023[4]. - Total liabilities as of June 30, 2024, were HKD 99.7 million, down from HKD 124.5 million as of June 30, 2023[5]. - The total outstanding bank financing was approximately HKD 108,400,000 as of June 30, 2024, with HKD 45,300,000 remaining undrawn[49]. - The group reported bank borrowings of HKD 63,119,000 in 2024, a decrease from HKD 65,525,000 in 2023[30]. - The debt-to-capital ratio was approximately zero as of June 30, 2024, consistent with the previous year[53]. Employee Expenses - The group’s employee benefit expenses decreased to HKD 26.0 million from HKD 38.7 million year-on-year[2]. - Employee benefits expenses for the year were approximately HKD 26.0 million, down from HKD 38.7 million for the year ended June 30, 2023[43]. - Employee benefits expenses decreased from HKD 38,723,000 in 2023 to HKD 26,019,000 in 2024, a reduction of approximately 32.9%[15]. - The company's retirement benefit costs for the defined contribution plan decreased from HKD 1,403,000 in 2023 to HKD 1,219,000 in 2024, a decrease of approximately 13.1%[15]. - The company employed a total of 55 employees as of June 30, 2024, down from 62 employees in 2023[59]. Market and Business Strategy - The company continues to focus on expanding its healthcare staffing solutions and vaccination services in Hong Kong, aiming for market growth[7]. - The group aims to strengthen its core business and become a more recognized market leader in response to the increasing demand for healthcare staffing solutions[39]. - The group plans to adopt a prudent capital policy to safeguard shareholder financial interests amid uncertainties in the capital market for 2025 and 2026[39]. - The group continues to focus on providing healthcare staffing solutions and related services, adapting to market demands and regulatory changes[11]. Financial Reporting and Governance - The company has implemented new accounting standards effective from July 1, 2023, which may influence future financial reporting[9]. - The company has not adopted any new or revised Hong Kong Financial Reporting Standards that would significantly impact the consolidated financial statements in the foreseeable future[10]. - The company has adhered to the corporate governance code and standards throughout the year[65]. - The board of directors will continue to review the effectiveness of the corporate governance structure, including the separation of the roles of Chairman and CEO[67]. - The audit committee, consisting of three independent non-executive directors, has approved the nature and scope of the statutory audit for the year[68]. Share Capital and Options - The group issued a total of 402,460,000 ordinary shares as of June 30, 2024, including 2,460,000 shares issued under the share incentive plan[28]. - The company has 8,900,000 unexercised stock options available for exercise at an average exercise price of HKD 1.192 per option[32]. - The stock option plan allows for a maximum of 10% of the total issued shares to be granted, with no new options issued during the current year[33]. - The company granted a total of 2,460,000 reward shares under the share reward plan to 21 participants, which will be implemented through a trustee[34]. - The total number of shares issued under the share reward plan as of June 30, 2024, is 2,380,000, representing 0.59% of the total issued shares[35]. Future Outlook - The company will hold its annual general meeting on November 28, 2024[70]. - The company will issue its annual report, which includes all information required by listing rules, in due course[74].

Financial Performance - Revenue for the six months ended December 31, 2023, was approximately HKD 49.7 million, a decrease of about 26.6% compared to approximately HKD 67.7 million for the same period in 2022[5] - Profit before tax for the six months ended December 31, 2023, was approximately HKD 21.0 million, down approximately 44.9% from approximately HKD 38.1 million for the same period in 2022[5] - Profit attributable to equity holders for the six months ended December 31, 2023, was approximately HKD 17.1 million, a decrease of about 44.1% compared to approximately HKD 30.6 million for the same period in 2022[5] - The company reported a total comprehensive income of HKD 15.8 million for the six months ended December 31, 2023, compared to HKD 30.0 million for the same period in 2022[8] - The net loss for the period was approximately HKD 1,900,000, compared to a net loss of HKD 700,000 for the six months ended December 31, 2022, primarily due to fair value changes in financial assets measured at fair value through profit or loss amounting to approximately HKD 1,800,000[66] Dividends - The board declared an interim dividend of HKD 20.1 million (5.0 HK cents per share) for the six months ended December 31, 2023[5] - The group declared an interim dividend of HKD 15,000,000 for the six months ended December 31, 2023, compared to HKD 20,000,000 for the same period in 2022[41] - The board declared an interim dividend of HKD 0.05 per ordinary share, totaling HKD 20,123,000, to be paid on March 22, 2024[126] Assets and Liabilities - Total assets as of December 31, 2023, were HKD 327.9 million, down from HKD 346.8 million as of June 30, 2023[10] - Total liabilities as of December 31, 2023, were HKD 104.7 million, a decrease from HKD 124.5 million as of June 30, 2023[11] - The company's cash and bank balances decreased to HKD 22.9 million from HKD 93.3 million as of June 30, 2023[10] - The company's equity attributable to equity holders increased to HKD 223,190,000 as of December 31, 2023, up from HKD 220,667,000[13] - The company’s retained earnings increased to HKD 178,731,000 as of December 31, 2023, compared to HKD 175,933,000 at the end of the previous period[13] Cash Flow - For the six months ended December 31, 2023, the company reported a net cash outflow from operating activities of HKD (501,000) compared to HKD 5,923,000 in the same period of 2022[14] - The net cash outflow from investing activities was HKD (1,835,000), a decrease from HKD 3,128,000 in the previous year[14] - The net cash outflow from financing activities was HKD (16,212,000), compared to HKD (22,280,000) in the prior year, indicating an improvement[14] Revenue Breakdown - Revenue from healthcare staffing solutions for the six months ended December 31, 2023, was HKD 40,674,000, a decrease of 29.8% compared to HKD 57,950,000 in the same period of 2022[27] - Total revenue for the group for the six months ended December 31, 2023, was HKD 49,703,000, down 26.6% from HKD 67,689,000 in the previous year[27] Expenses - Total expenses for the group decreased to HKD 155,490,000 in 2023 from HKD 218,749,000 in 2022, representing a reduction of 29%[29] - Employee benefits expenses for the period were approximately HKD 12,200,000, a decrease of about HKD 1,200,000 compared to HKD 13,400,000 for the six months ended December 31, 2022[67] - The group’s income tax expense for the six months ended December 31, 2023, was HKD 3,893,000, a decrease from HKD 7,549,000 in the same period of 2022[35] Shareholder Information - Major shareholder Xi Xiaozhu holds 270,200,000 shares, representing 67.14% of the company's equity[101] - HRnet Group Limited owns 32,000,000 shares, accounting for 8.0% of the company's equity[101] - The company reported a total of 402,460,000 shares issued as of December 31, 2023[96] Stock Options and Incentives - The company adopted a share incentive plan on June 1, 2022, with a total authorized limit of 40,000,000 shares, representing 10% of the issued share capital at the time[109] - A total of 2,460,000 reward shares were granted to 21 eligible participants under the share incentive plan, which will be held in trust until the vesting conditions are met[111] - The total number of employee stock options granted during the year was 4,390,000, with 190,000 options forfeited, resulting in a total of 4,200,000 options outstanding[107] Corporate Governance - The board is committed to maintaining high standards of corporate governance and transparency[120] - The audit committee has reviewed the unaudited consolidated financial results and interim report, affirming the accounting principles adopted by the company[124] - The company has not made any changes to its corporate governance structure regarding the separation of the roles of chairman and CEO, which are currently held by the same individual[123]

Revenue and Profit Performance - The group's revenue for the six months ended December 31, 2023, was approximately HKD 49,700,000, a decrease of about 26.6% compared to HKD 67,700,000 for the same period last year[8]. - Profit attributable to equity holders for the same period was approximately HKD 17,100,000, down approximately 44.1% from HKD 30,600,000 year-on-year[15]. - Revenue from healthcare staffing solutions was approximately HKD 40,700,000, a decrease of about 29.8% from HKD 58,000,000 in the previous year, primarily due to reduced demand for COVID-19 testing services[8]. - For the six months ended December 31, 2023, customer contract revenue was HKD 49,703,000, a decrease of approximately 26.6% from HKD 67,689,000 in the same period last year[44]. - Total comprehensive income for the period was HKD 15,836,000, down from HKD 30,022,000 year-on-year, representing a decline of approximately 47.3%[45]. - The operating profit for the six months ended December 31, 2023, was HKD 21,091,000, a decrease of about 45.4% compared to HKD 38,667,000 in the previous year[44]. - The company reported a basic and diluted earnings per share of 4.28 HKD cents, down from 7.65 HKD cents in the same period last year, reflecting a decline of approximately 44.5%[45]. - The company's profit before tax for the six months ended December 31, 2023, was approximately HKD 21 million, down approximately 44.9% from about HKD 38.1 million for the same period in 2022[56]. - The total comprehensive income for the six months ended December 31, 2023, was HKD 15.836 million, down from HKD 30.039 million for the same period in 2022[59]. - The net loss for the period was approximately HKD 1,900,000 (for the six months ended December 31, 2022: net loss of HKD 700,000)[150]. Cash Flow and Financial Position - Cash and bank balances as of December 31, 2023, were approximately HKD 74,700,000, down from HKD 93,300,000 as of June 30, 2023[18]. - The net cash used in operating activities for the six months ended December 31, 2023, was HKD (501,000), compared to HKD 5.9 million generated in the same period in 2022[49]. - The net cash used in investing activities for the six months ended December 31, 2023, was HKD (1.835 million), compared to HKD 3.128 million generated in the same period in 2022[49]. - The net cash used in financing activities for the six months ended December 31, 2023, was HKD (16.212 million), compared to HKD (22.280 million) in the same period in 2022[49]. - Cash and cash equivalents totaled HKD 74,723,000, down from HKD 93,269,000, a decrease of 19.8%[82]. - The company declared an interim dividend of HKD 20.123 million for the six months ended December 31, 2023, equivalent to HKD 0.05 per share[56]. - The company declared an interim dividend of HKD 0.05 per share, totaling HKD 20,123,000 based on the number of shares issued as of the announcement date[176]. - The group maintained a healthy liquidity position as of December 31, 2023, with working capital needs met through equity and cash generated from operations[122]. Expenses and Cost Management - Employee benefits expenses for the period were approximately HKD 12,200,000, a decrease of about HKD 1,200,000 compared to HKD 13,400,000 for the same period last year[13]. - Total expenses reduced to HKD 155,490,000 from HKD 218,749,000, a decrease of 28.9%[72]. - Other operating expenses for the period were approximately HKD 4,900,000 (for the six months ended December 31, 2022: HKD 6,000,000), a decrease of approximately HKD 1,100,000[151]. - Total employee costs for the period (including director remuneration) were approximately HKD 12,200,000 (for the six months ended December 31, 2022: HKD 13,400,000)[162]. Trade and Receivables - Trade payables increased from approximately HKD 24,600,000 as of June 30, 2023, to approximately HKD 26,200,000 as of December 31, 2023, representing a 6.5% increase year-on-year[16]. - Trade receivables increased to HKD 52,834,000 from HKD 46,272,000, representing an increase of approximately 14.5%[46]. - Trade receivables increased from approximately HKD 46,300,000 on June 30, 2023, to approximately HKD 52,800,000 on December 31, 2023, an increase of about HKD 6,500,000[121]. - The group did not recognize any provisions for trade receivables during the period, consistent with the previous year[121]. Strategic Initiatives and Future Outlook - The group aims to explore business opportunities and strategic partnerships to expand its operations beyond the current scale and position[10]. - The board remains optimistic about the continued growth of the company's core business in the coming years, driven by an aging population and increasing demand for healthcare staffing solutions[113]. - The group aims to solidify its market position and explore profitable long-term business growth opportunities[113]. Assets and Liabilities - As of December 31, 2023, total assets amounted to HKD 327,891,000, a decrease from HKD 346,828,000 as of June 30, 2023[47]. - The company had no significant or substantial debt as of December 31, 2023, with a capital debt ratio of zero[35][39]. - As of December 31, 2023, the total outstanding bank borrowings amounted to HKD 64,400,000, all of which are short-term loans[125]. - The group has no significant capital commitments as of December 31, 2023[127]. Financial Income and Investments - Financial income from short-term bank deposits increased to approximately HKD 856,000 from about HKD 22,000 in the previous year, an increase of approximately HKD 834,000[14]. - Financial income for the period was HKD 856,000, significantly up from HKD 22,000 in the previous year[44]. - The group did not sell any financial assets during the period but acquired financial assets worth approximately HKD 2,500,000, maintaining its primary investment objective of increasing excess cash and improving yield[85]. - The actual annual interest rate for bank deposits ranged from 4.95% to 5.36% as of December 31, 2023, compared to 1% to 4.8% on June 30, 2023[140]. Market and Operational Insights - The group’s major business operations are primarily located in Hong Kong, with all revenue generated from external customers in Hong Kong[95]. - Approximately 29,500 registered healthcare personnel were associated with the group as of December 31, 2023[144]. - The group’s cash and cash equivalents are primarily denominated in HKD and USD, minimizing foreign currency risk[124]. - Revenue from institutional staffing solutions decreased by approximately 39.7% to HKD 27,300,000 (for the six months ended December 31, 2022: HKD 45,300,000)[147]. - Revenue from private caregiver staffing services slightly decreased by approximately 5.5% to HKD 13,400,000 (for the six months ended December 31, 2022: HKD 12,700,000)[147]. - The company has not adopted new accounting standards that would significantly impact its accounting policies during the reporting period[92]. - The board believes that the global capital markets will continue to face severe challenges in 2024[145].

Revenue Performance - Revenue from healthcare staffing solutions for the year was approximately HKD 102,900,000, a decrease of about HKD 3,900,000 or 3.7% compared to HKD 106,900,000 for the year ended June 30, 2022[3][31]. - Institutional staffing solutions generated revenue of approximately HKD 68,500,000, down 8.9% from HKD 75,200,000 in the previous year[3]. - Private nursing staffing services maintained relative stability with revenue of approximately HKD 34,500,000, compared to HKD 31,700,000 in the previous year[3]. - Total revenue for the year decreased from HKD 140,300,000 to HKD 126,600,000, reflecting a decline due to reduced demand for vaccination services[24]. - Revenue from outreach case assessment and vaccination services decreased by approximately 56.5% to about HKD 12,300,000 due to the closure of community vaccination centers in Hong Kong[40]. - Revenue from customer contracts for 2023 was HKD 126,558 thousand, a decrease of 9.8% from HKD 140,295 thousand in 2022[104]. - Other income increased significantly to HKD 8,997 thousand in 2023 from HKD 4,106 thousand in 2022, representing a growth of 119.0%[104]. Profitability and Expenses - Profit attributable to equity holders for the year was approximately HKD 46,900,000, down about 20.0% from HKD 58,600,000 for the year ended June 30, 2022[39]. - Operating profit for 2023 was HKD 59,845 thousand, down 18.2% from HKD 73,159 thousand in 2022[104]. - Net profit for the year was HKD 46,919 thousand, a decrease of 20.0% compared to HKD 58,620 thousand in the previous year[105]. - Basic and diluted earnings per share for 2023 were 11.73 HK cents, down from 14.66 HK cents in 2022, reflecting a decline of 20.0%[104]. - Total comprehensive income for the year, after tax, was HKD 46,699 thousand, down from HKD 55,070 thousand in 2022, a decrease of 15.5%[105]. - Employee benefit expenses for the year were approximately HKD 38,700,000, a decrease from HKD 41,300,000 for the year ended June 30, 2022[36]. - Other operating expenses increased from approximately HKD 11,100,000 to about HKD 14,500,000, primarily due to increased costs related to the "LOUD ON AIR" concert[37]. Financial Position - Total revenue for the year was approximately HKD 126,600,000, a decrease of about 9.8% from HKD 140,300,000 for the year ended June 30, 2022[39]. - Total equity attributable to the company's equity holders increased to HKD 222,320,000 in 2023 from HKD 210,603,000 in 2022, representing a growth of 5.4%[79]. - Cash generated from operating activities decreased to HKD 60,833,000 in 2023 from HKD 120,157,000 in 2022, a decline of 49.3%[82]. - Net cash generated from operating activities was HKD 41,936,000 in 2023, down from HKD 116,111,000 in 2022, indicating a decrease of 64.1%[82]. - Total liabilities decreased to HKD 124,508,000 in 2023 from HKD 140,746,000 in 2022, a reduction of 11.6%[79]. - Cash and cash equivalents at the end of 2023 were HKD 93,269,000, up from HKD 86,268,000 at the end of 2022, reflecting an increase of 8.6%[82]. - The company paid dividends of HKD 35,000,000 in 2023, compared to HKD 40,000,000 in 2022, a decrease of 12.5%[82]. - The company reported a net cash outflow from investing activities of HKD 6,917,000 in 2023, contrasting with a significant outflow of HKD 111,630,000 in 2022[82]. Strategic Outlook - The board remains optimistic about the medium to long-term growth of the core business due to the increasing elderly population and ongoing hospital development plans[17]. - The company plans to hire more experienced healthcare professionals to enhance service quality and support business growth[25]. - The company is taking proactive steps to diversify its core business and expand its geographical coverage, particularly in the Greater Bay Area[26]. - The board is actively seeking business opportunities and strategic partnerships to enhance business development[4]. - The group anticipates that global capital markets will remain challenging in 2024, and will continue to adopt prudent capital management and liquidity risk management policies[41]. - The group aims to pursue long-term business opportunities and profitability growth despite the challenging market conditions[41]. Environmental and Regulatory Considerations - The company has established an environmental policy to reduce its environmental impact and promote sustainable practices[192]. - The company is monitoring updates to environmental laws and agreements to avoid unnecessary costs and expenditures due to non-compliance[198]. - The company recognizes the increasing customer consideration of climate-related risks and opportunities, which may change demand for its services[200]. - The company has taken steps to ensure that its business activities do not cause significant harm to the environment or natural resources[192]. - The company has implemented measures to manage physical climate risks, including safeguarding documents and equipment during extreme weather events like typhoons[195]. - The company has set a target to reduce energy consumption and greenhouse gas emissions to achieve net-zero emissions[192]. - The company is prepared for the transition to a low-carbon economy by understanding associated risks and opportunities[191]. - The company regularly assesses its operational situation to minimize its environmental impact[192]. Accounting and Financial Reporting - The company has full control over subsidiaries from the date control is transferred, and they are fully consolidated into the financial statements[119]. - The company uses the accounting acquisition method for business combinations, measuring identifiable assets and liabilities at fair value on the acquisition date[141][143]. - The financial statements are presented in Hong Kong dollars, which is the company's functional and reporting currency[147]. - Any foreign exchange differences arising from the translation of foreign operations are recognized in other comprehensive income[150]. - The company expects that new accounting standards and interpretations will not have a significant impact on its financial position and performance[140]. - Depreciation of property, plant, and equipment is calculated using the straight-line method over their estimated useful lives[133]. - Financial assets are classified into measurement categories, including those measured at amortized cost[156]. - The company applies a simplified approach for trade receivables, recognizing expected lifetime losses at initial recognition[163].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全 部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 BAMBOOS HEALTH CARE HOLDINGS LIMITED 百 本 醫 護 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：2293） 截 至 二 零 二 三 年 六 月 三 十 日 止 年 度 之 年 度 業 績 公 告 財務摘要 • 截至二零二三年六月三十日止年度的收益約126,600,000港元，較截至二 零二二年六月三十日止年度錄得約140,300,000港元減少約9.8%。 • 截至二零二三年六月三十日止年度的除所得稅前溢利約58,700,000港元， 較截至二零二二年六月三十日止年度錄得約72,400,000港元減少約18.9%。 • 截 至 二 零 二 三 年 六 月 三 十 日 止 年 度 的 本 公 司 權 益 持 有 人 應 佔 溢 利 約 46,900,000港元，較截至二零二二年六月三十日止年度錄得約58,600,000 港元減少約20.0%。 ...

Financial Performance - For the six months ended December 31, 2022, revenue was approximately HKD 67.7 million, a decrease of about 7.2% compared to approximately HKD 73.0 million for the same period in 2021[5] - Profit before tax for the same period was approximately HKD 38.1 million, down approximately 9.9% from approximately HKD 42.3 million in the prior year[5] - Profit attributable to equity holders for the six months ended December 31, 2022, was approximately HKD 30.6 million, a decrease of about 8.7% from approximately HKD 33.5 million in the previous year[5] - The company reported a total comprehensive income of HKD 30.0 million for the six months ended December 31, 2022, compared to HKD 30.3 million in the previous year[8] - The total comprehensive income for the six months ended December 31, 2022, was HKD 30,271,000, a decrease from HKD 33,493,000 in the previous year[13] - The company reported a profit of HKD 30,581,000 for the six months ended December 31, 2022, compared to HKD 33,493,000 in the same period of 2021[13] Dividends - The board declared an interim dividend of HKD 15.0 million (HKD 0.0375 per share) to shareholders on the register as of March 17, 2023[5] - The company declared a dividend of HKD 20,000,000 for the year 2022, which was a reduction from HKD 30,000,000 declared for 2021[13] - The board declared an interim dividend of HKD 0.0375 per ordinary share, compared to HKD 0.025 per share for the same period last year[112] - The total amount of the interim dividend to be distributed is approximately HKD 15,000,000[112] - The interim dividend will be paid on March 23, 2023, to shareholders listed as of the close of business on March 17, 2023[112] Assets and Liabilities - Total assets as of December 31, 2022, were HKD 342.8 million, a decrease from HKD 351.3 million as of June 30, 2022[10] - Total liabilities decreased to HKD 122.1 million as of December 31, 2022, from HKD 140.7 million as of June 30, 2022[11] - The company's cash and bank balances decreased to HKD 42.3 million from HKD 86.3 million as of June 30, 2022[10] - The company's retained earnings increased to HKD 150,688,000 as of December 31, 2022, up from HKD 148,025,000 at the beginning of the period[13] - The total equity attributable to equity holders of the company increased to HKD 220,667,000 as of December 31, 2022, from HKD 194,787,000 at the beginning of the period[13] Cash Flow - The net cash generated from operating activities for the six months ended December 31, 2022, was HKD 5,923,000, a decrease of 91.4% compared to HKD 69,097,000 in the same period of 2021[14] - The net cash used in investing activities for the six months ended December 31, 2022, was HKD 3,128,000, a significant improvement from HKD (127,122,000) in the previous year[14] - The net cash used in financing activities for the six months ended December 31, 2022, was HKD (22,280,000), compared to HKD 53,542,000 generated in the same period of 2021[14] Revenue Breakdown - Revenue from healthcare staffing solutions for the six months ended December 31, 2022, was HKD 57,950,000, an increase of 10.3% from HKD 52,241,000 in the same period of 2021[27] - Total revenue for the group for the six months ended December 31, 2022, was HKD 67,689,000, a decrease of 7.5% compared to HKD 73,036,000 in the previous year[27] - Revenue from healthcare staffing solutions increased by approximately HKD 5.8 million or 11.1% to about HKD 58 million, primarily due to demand from COVID-19 testing agencies[60] - Revenue from outreach case assessment services decreased by approximately HKD 16.6 million to about HKD 4.2 million, mainly due to reduced demand for medical and health assessment services[60] - Institutional staffing solutions generated revenue of approximately HKD 45,300,000, representing a 27.3% increase from HKD 35,600,000 in the same period last year[64] Expenses - Total expenses for the group increased to HKD 218,749,000 in the six months ended December 31, 2022, from HKD 190,995,000 in the same period of 2021, representing a rise of 14.5%[29] - The cost of healthcare personnel accounted for HKD 160,799,000 of total expenses, up from HKD 138,754,000 in the previous year, marking an increase of 15.9%[29] - Employee benefits expenses were approximately HKD 13,400,000, an increase of about 6.3% from HKD 12,600,000 in the same period last year[68] Taxation - The company incurred a tax expense of HKD 7,549,000 for the six months ended December 31, 2022, compared to HKD 8,788,000 in the same period of 2021, a decrease of 14.1%[35] Corporate Governance - The board of directors has confirmed compliance with the corporate governance code throughout the reporting period[107] - The company maintains a high standard of corporate governance to protect the interests of shareholders and ensure effective management[108] - The roles of the chairman and CEO are currently held by the same individual, which deviates from the corporate governance code, but the board believes this structure is effective[109] Shareholder Information - The company’s major shareholder, Ms. Xi Xiaozhu, held a 67.55% equity interest in the company as of December 31, 2022[96] - Gold Empress holds 270,200,000 shares, representing 67.55% of the company's equity[101] - HRnet Group Limited owns 32,000,000 shares, accounting for 8.0% of the company's equity[101] Employment - The company employed a total of 69 employees as of December 31, 2022, a decrease from 72 employees as of December 31, 2021[90]